NeuroTech AI

NeuroTech AI sits at the intersection of digital health, computer vision, movement analysis, and sports technology. Its proposed distinction is the use of table tennis as a repeatable activity for capturing complex motor behavior, with AI models intended to identify deviations that could merit further clinical assessment. The relevant competitive landscape likely includes digital neurological assessment tools, video-based movement-analysis systems, and clinical screening products; NeuroTech AI’s stated point of differentiation is its table-tennis setting and motion-pattern analysis. The product is described as supporting Parkinson’s and related conditions, but clinical validation remains planned. That development stage is an important constraint: differentiation in the intended workflow does not yet demonstrate diagnostic accuracy, regulatory readiness, or adoption. The company’s competitive position therefore depends on validating its measurements and showing that they add useful, accessible information to clinical practice.

NeuroTech AI’s trajectory is at an early development stage. The company’s listed founding date is Jan 27, 2026, and its central product, TT Neuro AI, is described as an AI-based system for analyzing table-tennis movement. The proposed product path spans screening, monitoring, and research, with potential deployment through sports clubs, rehabilitation centers, healthcare providers, and individual subscriptions. These are stated use cases rather than confirmed commercial deployments. Clinical validation is planned, making evidence generation a key inflection point: results from validation would help clarify whether motion signals can support reliable assessment and whether the system can fit clinical workflows. The financial signals identify a Seed round without an amount or date, while a separate growth signal says the company is seeking pre-seed funding to accelerate growth; the financing stage and any completed raise are therefore not fully clear. A €2M pre-money valuation is associated with a 2026–2027 roadmap, but no valuation date is specified. Near-term progress is best assessed through validation, product readiness, and evidence of deployment rather than assumed scale.